Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1991 5
1992 4
1993 2
1994 4
1995 2
1998 4
1999 2
2000 4
2001 5
2002 4
2003 13
2004 9
2005 7
2006 4
2007 9
2008 9
2009 6
2010 9
2011 13
2012 12
2013 7
2014 12
2015 16
2016 19
2017 20
2018 15
2019 16
2020 8
2021 16
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

226 results
Results by year
Filters applied: . Clear all
Page 1
Etanercept for the treatment of rheumatoid arthritis.
Zhao S, Mysler E, Moots RJ. Zhao S, et al. Among authors: moots rj. Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27. Immunotherapy. 2018. PMID: 29482402 Review.
2018 update of the EULAR recommendations for the management of Behçet's syndrome.
Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. Hatemi G, et al. Among authors: moots r. Ann Rheum Dis. 2018 Jun;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6. Ann Rheum Dis. 2018. PMID: 29625968
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Among authors: moots rj. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Among authors: moots r. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
226 results